Toggle menu
Toggle preferences menu
Toggle personal menu
Not logged in
Your IP address will be publicly visible if you make any edits.

Carbamazepine

From Pharmacopedia
Revision as of 00:35, 22 May 2026 by MDElliottMD (talk | contribs) (Category taxonomy ship: retag Anticonvulsants -> Antiepileptics)
Mood Stabilizer, Anticonvulsant
Carbamazepine
Tegretol

Experience

👥 No personal reports yet
No clinical reports yet

Log in to add your own experience.

Problems

No problems yet. Be the first to suggest one.

+ Add a problem

Titration strategies

No titration strategies yet. Be the first to suggest one.

+ Add a titration strategy

Effects

No effects listed yet. Be the first to suggest one.

+ Add an effect

Interactions

Pharmacogenomic + mechanism interactions10 edges
Pharmacogenomic guideline recommendationsCPIC and Dutch Pharmacogenetics Working Group clinical guidelines
Variant:hla-a 3101 pos contraindication CPIC A 90 / 100
CPIC rec 8093545 [Strong]: If patient is carbamazepine-naïve and alternative agents are available, do not use carbamazepine. CPIC pair-level A (HLA-A, HLA-B and Carbamazepine and Oxcarbazepine) [PMID 23695185, 29392710]
Variant:hla-b 1502 neg contraindication CPIC A 90 / 100
CPIC rec 8093545 [Strong]: If patient is carbamazepine-naïve and alternative agents are available, do not use carbamazepine. CPIC pair-level A (HLA-A, HLA-B and Carbamazepine and Oxcarbazepine) [PMID 23695185, 29392710]
Variant:hla-a 3101 neg contraindication CPIC A 90 / 100
CPIC rec 8093547 [Strong]: If patient is carbamazepine-naïve, do not use carbamazepine. CPIC pair-level A (HLA-A, HLA-B and Carbamazepine and Oxcarbazepine) [PMID 23695185, 29392710]
Variant:hla-b 1502 pos contraindication CPIC A 90 / 100
CPIC rec 8093547 [Strong]: If patient is carbamazepine-naïve, do not use carbamazepine. CPIC pair-level A (HLA-A, HLA-B and Carbamazepine and Oxcarbazepine) [PMID 23695185, 29392710]
Variant:hla-a 3101 pos risk hypersensitivity CPIC A 30 / 100
CPIC rec 8093554 [Optional]: If patient is carbamazepine-naïve and alternative agents are not available, consider the use of carbamazepine with increased frequency of clinical monitoring. Discontinue therapy at first evidence of a cutaneous adverse reaction. CPIC pair-level A (HLA-A, HLA-B and Carbamazepine and Oxcarbazepine) [PMID 23695185, 29392710]
Variant:hla-b 1502 neg risk hypersensitivity CPIC A 30 / 100
CPIC rec 8093554 [Optional]: If patient is carbamazepine-naïve and alternative agents are not available, consider the use of carbamazepine with increased frequency of clinical monitoring. Discontinue therapy at first evidence of a cutaneous adverse reaction. CPIC pair-level A (HLA-A, HLA-B and Carbamazepine and Oxcarbazepine) [PMID 23695185, 29392710]
Variant:hla-b 1502 pos risk hypersensitivity CPIC A 20 / 100
CPIC rec 8093564 [Optional]: The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (~4-28 days), and cases usually occur within three months of dosing; therefore, if the patient has previously used carbamazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine in the future. CPIC pair-level A (HLA-A, HLA-B and Carbamazepine and Oxcarbazepine) [PMID 23695185, 29392710]
Pharmacokinetic mechanismSubstrate / metabolism relationships from primary literature
Enzyme:CYP3A4 inducer strong Primary 90 / 100
FDA Drug Interactions Table: strong inducer of CYP3A4.
Inferred from pharmacokinetic dataMaterialised by the inference engine; provenance shown per row
Midazolam pk lowers via CYP3A4 Inferred 72 / 100
Carbamazepine induces CYP3A4 (inducer_strong, intensity 90); Midazolam is a substrate_major of CYP3A4 (intensity 80). Derived: Midazolam exposure lowered.
Inferred via Enzyme:CYP3A4 (exposure lowered)
Triazolam pk lowers via CYP3A4 Inferred 72 / 100
Carbamazepine induces CYP3A4 (inducer_strong, intensity 90); Triazolam is a substrate_major of CYP3A4 (intensity 80). Derived: Triazolam exposure lowered.
Inferred via Enzyme:CYP3A4 (exposure lowered)

Patient experience

No patient-experience reports yet.

Relevant anecdote

No anecdotes yet. Share a relevant one.

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

Summary
Classes
Mood Stabilizer, Anticonvulsant
Common uses
Pharmacy
Pharmacology
Purported mechanism
Sodium channel blocker